JP2024535871A5 - - Google Patents

Info

Publication number
JP2024535871A5
JP2024535871A5 JP2024517078A JP2024517078A JP2024535871A5 JP 2024535871 A5 JP2024535871 A5 JP 2024535871A5 JP 2024517078 A JP2024517078 A JP 2024517078A JP 2024517078 A JP2024517078 A JP 2024517078A JP 2024535871 A5 JP2024535871 A5 JP 2024535871A5
Authority
JP
Japan
Prior art keywords
thc
pharmaceutical product
product according
compound
rutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076579 external-priority patent/WO2023044433A1/en
Publication of JP2024535871A publication Critical patent/JP2024535871A/ja
Publication of JP2024535871A5 publication Critical patent/JP2024535871A5/ja
Pending legal-status Critical Current

Links

JP2024517078A 2021-09-17 2022-09-16 アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法 Pending JP2024535871A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17
US63/245,799 2021-09-17
PCT/US2022/076579 WO2023044433A1 (en) 2021-09-17 2022-09-16 Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin

Publications (2)

Publication Number Publication Date
JP2024535871A JP2024535871A (ja) 2024-10-02
JP2024535871A5 true JP2024535871A5 (enExample) 2025-09-25

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517078A Pending JP2024535871A (ja) 2021-09-17 2022-09-16 アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20250275935A1 (enExample)
EP (1) EP4401717A1 (enExample)
JP (1) JP2024535871A (enExample)
CA (1) CA3232209A1 (enExample)
CL (1) CL2024000782A1 (enExample)
CO (1) CO2024004628A2 (enExample)
PE (1) PE20241236A1 (enExample)
WO (1) WO2023044433A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
CN121040357A (zh) * 2024-06-04 2025-12-02 河北农业大学 一种增加黄水仙生物碱加兰他敏的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
EP4025199A4 (en) * 2019-07-12 2023-08-02 University of South Florida Compositions and methods for treating alzheimers disease

Similar Documents

Publication Publication Date Title
WO2021123804A1 (en) Oral cannabinoid formulations
US12171774B2 (en) Topical analgesic
Roy et al. Anti-inflammatory effects of different dietary antioxidants
EP3858364B1 (en) Food and beverage compositions infused with lipophilic active agents and methods of use thereof
TWI527582B (zh) 生育三烯酚組合物
RU2018107713A (ru) Композиции на основе флавоноидов и способы применения
US20030105031A1 (en) Methods for the treatment of skin disorders
US20190151398A1 (en) Pharmaceutical Composition Comprising Cannabidiol (CBD) and Lecithin
CA3013573A1 (en) Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process
KR20220152198A (ko) 경구 용해성 필름 및 그의 제조 및 사용 방법
Jayusman et al. Therapeutic potential of polyphenol and nanoparticles mediated delivery in periodontal inflammation: A review of current trends and future perspectives
MX2007007038A (es) Formulacion de dronabinol en temperatura ambiente.
CA2454644A1 (en) Cannabinoid liquid formulations for mucosal administration
JP2013241471A (ja) 神経因性疼痛の治療用カンナビノイド
Hendawy Nano-Delivery Systems for Improving Therapeutic Efficiency of Dietary Polyphenols.
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
Zhong et al. Dietary polyphenols ameliorate inflammatory bowel diseases: advances and future perspectives to maximize their nutraceutical applications
Akkewar et al. Mangiferin: A natural bioactive immunomodulating glucosylxanthone with potential against cancer and rheumatoid arthritis
EP3826630B1 (en) Cannabinoids compositions with polyunsaturated fatty acid monoglycerides and use thereof
Sun et al. Phytonutrients as potential dietary supplements to ameliorate sarcopenia via the involvement of autophagic pathway
US20230125099A1 (en) Oronasal cbd formulations and uses thereof
JP2001064172A (ja) Ａｐｃ遺伝子の変異に起因する疾患の予防・治療剤
JP2024535871A (ja) アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法
JP5551326B2 (ja) 閉経後の女性および下等動物における脂溶性ビタミンの腸吸収を増進する際の方法
WO2004064725A2 (en) Oral compositions and methods for treatment of adverse effects or radiation